ResMed: A Significant Upside Despite The Perceived Risk

ResMed has de-rated from 30x to below 21x earnings despite 17% EPS growth, suggesting valuation compression has been driven more by market narrative than fundamentals. Recurring masks and consumables revenue, representing 42% of its sleep and breathing segment, grew 13% last year; perceived risks from sleep-apnea drugs and reimbursement appear overstated, while Philips' potential U.S. re-entry remains the principal competitive risk.

Analysis

RMD’s valuation discount creates an asymmetric setup because its installed base monetization dampens the usual medtech dependence on new device placements. The key underwriting variable is not merely device unit growth but whether high-margin replenishment revenue sustains low-double-digit growth; if it does, incremental gross margin and operating leverage should support earnings revisions even with modest machine demand. A return toward RMD’s historical mid-20x forward P/E would imply meaningful upside over 6-12 months without requiring an acceleration in reported EPS growth.

The market is likely overstating substitution from GLP-1-based sleep-apnea treatment. Drug therapy may reduce severity for a subset of obese patients, but it also expands diagnosis and physician engagement, while many patients retain PAP therapy during weight loss or lack durable adherence to injectable regimens. The more immediate competitive variable is PHG’s ability to rebuild U.S. distribution, service capacity, and payer confidence; that is a 12-24 month share-risk rather than a near-term revenue cliff, but any evidence of PHG winning meaningful new-patient placements could pressure RMD’s device pricing before it shows up in reported share data.

Near-term catalysts are quarterly mask-growth, U.S. sleep-lab referral trends, and evidence that payer policy does not force broader PAP reimbursement friction. The thesis is falsified if consumables growth falls below high-single digits for two consecutive quarters, if gross margin contracts despite mix support, or if management cuts device-market growth expectations. Contrarian risk is that the multiple remains compressed if investors treat RMD as a mature durable-equipment name rather than a recurring-revenue healthcare platform; therefore the trade requires earnings-confirmation rather than a purely multiple-driven entry.

Key Decisions for Investors

• Initiate a 6-12 month long RMD position on post-earnings weakness or before the next quarterly print, sized to a base case of multiple normalization toward 24-25x forward earnings. Target 15-25% total return; reduce if replenishment revenue growth drops below 9% or if management signals material U.S. pricing concessions.
• Express the competitive view as long RMD / short PHG in equal dollar amounts over 6-12 months, rather than an outright RMD-only position. RMD’s recurring consumables mix should provide better downside resilience, while PHG carries execution risk around rebuilding sleep-market access; close the spread if PHG demonstrates sustained U.S. sleep-device share gains or RMD’s consumables growth decelerates materially.
• Do not position around sleep-apnea drug headlines alone. Set an alert for payer coverage expansion, real-world discontinuation data, and evidence of PAP discontinuation among treated patients; a demonstrated decline in PAP adherence rather than drug prescription growth would be the actionable negative signal for RMD.
• Use the next earnings release as the primary 1-3 month catalyst: add only if management confirms consumables growth remains at least low-double-digit and maintains operating-margin trajectory. A beat driven solely by device backlog or favorable FX, without recurring-revenue confirmation, should not trigger incremental buying.